2012
CD24-Siglec-G Interaction Plays an Important in Reducing Experimental Graft-Versus-Host Disease (GVHD)
Toubai T, Evers R, Sun Y, Tawara I, Liu C, Tamaki H, Mathewson N, Nieves E, Bassetti M, Zheng P, Liu Y, Reddy P. CD24-Siglec-G Interaction Plays an Important in Reducing Experimental Graft-Versus-Host Disease (GVHD). Blood 2012, 120: 453. DOI: 10.1182/blood.v120.21.453.453.Peer-Reviewed Original ResearchHost antigen presenting cellsAntigen presenting cellsBALB/c donorsT cellsWT B6Allogeneic BMTImmunoreceptor tyrosine-based inhibitory motifWorse survivalSerum levelsImmune activationBM chimerasDonor T cell expansionAllogeneic T-cell responsesT cell responsesBALB/c T cellsPro-inflammatory cytokinesT cell expansionRelevant murine modelRole of SiglecsC donorsIg-like lectinsIntensity of conditioningGraft-VersusGVHD mortalityHigher GVHD
2010
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation: A shifting Paradigm for T Cell Allo-activation
Silva I, Olkiewicz K, Askew D, Fisher J, Chaudhary M, Vannella K, Deurloo D, Choi S, Pierce E, Clouthier S, Liu C, Cooke K. Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation: A shifting Paradigm for T Cell Allo-activation. Transplantation And Cellular Therapy 2010, 16: 598-611. PMID: 20117226, PMCID: PMC3838892, DOI: 10.1016/j.bbmt.2009.12.007.Peer-Reviewed Original ResearchConceptsSecondary lymphoid organsDonor T cellsAllogeneic bone marrow transplantationAly/aly miceBone marrow transplantationAntigen-presenting cellsPeyer's patchesT cellsAllo-BMTLymph nodesMarrow transplantationAly miceLymphoid organsAllogeneic T-cell responsesHost antigen-presenting cellsInduction of GVHDInduction of graftT cell responsesT cell activationDisparate donorsHost diseaseBMT recipientsMajor complicationsTumor burdenLeukemia activity
2007
CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation
Choi S, Hildebrandt G, Olkiewicz K, Hanauer D, Chaudhary M, Silva I, Rogers C, Deurloo D, Fisher J, Liu C, Adams D, Chensue S, Cooke K. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 2007, 110: 3447-3455. PMID: 17641205, PMCID: PMC2200916, DOI: 10.1182/blood-2007-05-087403.Peer-Reviewed Original ResearchConceptsStem cell transplantationT cell responsesCCR1 expressionHost diseaseT cellsAllogeneic T-cell responsesAllogeneic stem cell transplantationCCR1-deficient miceDevelopment of GVHDCytolytic effector functionDonor cellsT cell functionChemokine receptor-ligand interactionsT cell proliferationHost target tissuesReceptor-ligand interactionsActivated T cellsAcute graftGVHD mortalityGVL activityIFNgamma secretionAllo-SCTGVHD severityLeukemic infiltrationLeukemic relapse
2005
Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.
Choi S, Hildebrandt G, Silva I, Olkiewicz K, Chensue S, Liu C, Chaudhary M, Fisher J, Lane T, Cooke K. Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation. Blood 2005, 106: 3107. DOI: 10.1182/blood.v106.11.3107.3107.Peer-Reviewed Original ResearchT cell responsesGVL effectAllo-SCTT cellsCell responsesChemokine receptorsAllogeneic T-cell responsesAllo-SCT recipientsDonor T-cell alloreactivityGVHD target tissuesSerum IFNγ levelsSeverity of GVHDTarget tissuesLeukemia-free survivalClinical scoring systemBone marrow transplantationT cell expansionT-cell alloreactivityBone marrow inoculumHost target tissuesActivated T cellsP815 tumor cellsDose-dependent mannerHigher tumor dosesAcute graft
2002
Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease
Teshima T, Reddy P, Lowler K, KuKuruga M, Liu C, Cooke K, Ferrara J. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease. Blood 2002, 99: 1825-1832. PMID: 11861301, DOI: 10.1182/blood.v99.5.1825.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdjuvants, ImmunologicAnimalsBone Marrow TransplantationCD8 AntigensCell DivisionCoculture TechniquesDendritic CellsDisease Models, AnimalFemaleGraft vs Host DiseaseLymphocyte ActivationMembrane ProteinsMiceMice, Inbred C57BLSurvival RateT-LymphocytesTransplantation, HomologousConceptsDendritic cellsT cell responsesAcute graftHost diseaseDonor T-cell responsesAllogeneic bone marrow transplantationAllogeneic T-cell responsesAllogeneic bone marrow transplantExperimental acute graftHost dendritic cellsPoor stimulatory capacityNormal dendritic cellsAllogeneic T cellsBone marrow transplantationTreatment of miceBone marrow transplantFL treatmentAcute GVHDGVHD mortalityDC subsetsAllogeneic lymphocytesDC numbersMarrow transplantationLigand therapyMarrow transplant